Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01279291 · ClinicalTrials.gov registry record · Phase 1
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01279291: Clinical Trial Phase 1 study, sponsored by Kyowa Kirin Co..
NCT01279291 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01279291, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
Primary Outcome
The safety of KHK2866 will be determined by reported adverse events (AEs), changes in physical examinations, vital sign measurements, electrocardiograms (ECGs), clinical laboratory evaluations, and treatment discontinuation due to toxicity.
Interventions
- DRUG pegylated liposomal doxorubicin
- DRUG paclitaxel
- BIOLOGICAL KHK2866
- DRUG Gemcitabine and Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Why NCT01279291 stopped before completion
NCT01279291 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 4 interventions - of which pegylated liposomal doxorubicin is the first listed.
NCT01279291 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01279291 about?
NCT01279291 is a clinical study titled "Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer". This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.
What is the current status of trial NCT01279291?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01279291?
The interventions under investigation include: pegylated liposomal doxorubicin (DRUG), paclitaxel (DRUG), KHK2866 (BIOLOGICAL), Gemcitabine and Carboplatin (DRUG).
Who is sponsoring clinical trial NCT01279291?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01279291's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia